• Hyeon Kang Koh, Younghee Park, Taeryool Koo, Hae Jin Park, Me Yeon Lee, Ah Ram Chang, Semie Hong, and Hoonsik Bae.
• Department of Radiation Oncology, Konkuk University School of Medicine and Konkuk University Medical Center, Seoul, Republic of Korea.
• In Vivo. 2021 Mar 1; 35 (2): 1133-1139.

Background/AimLymphocyte-to-monocyte ratio, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio represent systemic immune-inflammatory responses. We evaluated the association between immune-inflammatory cell ratios and prognosis in esophageal squamous cell carcinoma (ESCC) patients who underwent definitive concurrent chemoradiotherapy (dCCRT).Patients And MethodsMedical records of 68 ESCC patients in three institutions who underwent dCCRT between 2006 and 2017 were reviewed. The immune-inflammatory cell ratios were calculated before and after dCCRT.ResultsThe median follow-up time was 11.4 months. The 3-year overall survival (OS) rate was 21.6%. Among the immune-inflammatory cell ratios, lower post-dCCRT neutrophil-to-lymphocyte ratio (NLRpost) was associated with better OS (median 15.2 vs. 9.7 months, p=0.030). Patients with lower NLRpost had more improved OS when adjuvant chemotherapy was administered following dCCRT (median 16.6 vs. 4.8 months, p<0.001).ConclusionNLRpost may be useful in predicting OS in ESCC patients after dCCRT. Furthermore, NLRpost might play a role in establishing adjuvant therapy plans following dCCRT.Copyright© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

14 keywords...

hide…